top of page
Picture.png

Unleashing the true potential of immuno-oncology.

Technology

Multi-Specific Nanofilament Immunotherapy

TATUM Bioscience is redefining cancer treatment with multi-specific nanofilament immunotherapy. Our breakthrough technology boosts tumor visibility, restores immune function, and drives lasting antitumor responses—positioning TATUM at the forefront of next-generation immuno-oncology.

(NC) 1 oct Démonte ton mythe QC_edited.png
Technology 1.png

Nanofilaments are injected
intratumorally

Our technology

Team

Management 

AI5A1921.jpg

Jean-François Millau, PhD

CEO and co-founder

  • LinkedIn
AI5A2356.jpg

Kevin Neil, PhD

CSO and co-founder

  • LinkedIn
Veronique.jpg

Veronique Riethuisen, MSc

CFO

  • LinkedIn
Alexandre.jpg

Alexandre LeBeaut, MD

CMO

  • LinkedIn

Board members

Jacques.jpg

Jacques Dessureault, MSc, C.Dir., CCA

Chairman of the board

  • LinkedIn
AI5A1921.jpg

Jean-François Millau, PhD

CEO TATUM bioscience

  • LinkedIn
marc Rivière.jpg

Marc Rivière, MD

General Partner and CMO at TVM Capital

  • LinkedIn
rebecca.jpg

Rebecca Allan, PhD

Investment Manager Life Sciences at BoxOne Venture

  • LinkedIn
Jesse.jpg

Jesse Paterson, MSc

Senior Director Business Development at CQDM

  • LinkedIn
Contact

Let's get in touch

For general inquiries contact us at: ​​​

info_tatumbio.com.png

To become a TATUMer and join the team send your motivation letter at: 

jobs_tatumbio.com.png

Thank you for contacting us!

TATUM bioscience is proudly supported by:

BoxOne - Investor.png
ACET accelerator.png
SCBio-Drive- Accelerator.png
adMare Accelerator.png
cqdm Investor.png
MaRS Accelerator.png
CBV Accelerator.png
creative-destruction-lab Accelerator.png
IQ Investor.png

©2025 TATUM Bioscience Inc. Background image by Design Cell.

bottom of page